Scientific Program
The Group’s scientific program includes all phases of clinical research (phases 1 to 4). It also covers all types and subtypes of breast cancer: Hormone-receptor-positive – estrogen or progesterone (HR +); HER2 protein overexpression (HER2 +); Triple-negative, which does not involve hormone receptors nor those of the HER2 protein (HR- / HER2-); Genetic mutation (somatic / spontaneous or hereditary / transmitted), as well as all stages of the disease or extent of cancer, from in situ and early stages to metastatic cancer.
| Cancer Subtype | Time of treatment | Treatment Types |
|---|---|---|
| HR+/HER2- | Neoadjuvant | Chemotherapy |
| HR-/HER2+ | Adjuvant | Hormonal therapy |
| HR-/HER2- (mutated or not) | Post-Neoadjuvant | Immunotherapy |
| HR+/HER2+ | Prevention | |
| Genetic Mutations | Radiation therapy | |
| Supportive therapy | ||
| Surgery | ||
| Targeted therapy |
Clinical Trials Performed Within the Group
The consortium is presently involved in over 40 or so clinical trials and is considering new ones regularly. Please refer to the table below which only lists trials that are currently in preparation or in recruitment at the Group’s hospitals.
How to use this table:
– Use the arrows to sort the columns in alphabetical order (in particular to sort the studies by status)
– Use the Search field with any keyword (hospital centre, cancer subtype etc.)
| Cancer Subtype | Study Name | Sponsor | Participating Hospitals | Status |
|---|---|---|---|---|
| HR+/HER2- | SERENA-4 A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL | In recruitment |
| HR+/HER2- | CAPItello-292 A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HER2+ | HER2CLIMB-05 A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer | Seagen | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU SAGUENAY-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR- & HER2- (triple negative) | TROPION-Breast-03 A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response at the Time of Surgery Following Neoadjuvant Therapy | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) | In recruitment |
| HR+ & HER2- | CELC-G-301 A phase 3, open-label, randomized, two-part study comparing gedatolisib in combination with palbociclib and fulvestrant to standard-of-care therapies in patients with hr-positive, her2-negative advanced breast cancer previously treated with a cdk4/6 inhibitor in combination with non-steroidal aromatase inhibitor therapy (viktoria-1) | Celcuity | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR+ & HER2- | CAMBRIA-1 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer | Astra Zeneca | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In preparation |
| HR- & HER2- (triple négatif) | TROPION-Breast-04 A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer | Astra Zeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE - CHUS CISSS DE CHAUDIÈRE-APPALACHES | In recruitment |
| HR+ & HER2- | INAVO-121 A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy | Hoffmann-LaRoche | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU NORD-DE-L’ÎLE-DE-MONTRÉAL / HÔPITAL DU SACRÉ-CŒUR-DE-MONTRÉAL | In recruitment |
| HR+ or HR- & HER2+ | INAVO-122 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Hoffmann-LaRoche | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU NORD-DE-L’ÎLE-DE-MONTRÉAL / HÔPITAL DU SACRÉ-CŒUR-DE-MONTRÉAL | In recruitment |
| HR+ & HER2- | pionERA Breast Cancer A Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. | Hoffmann-LaRoche | CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR+ & HER2- | Adjuvant WIDER A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer | Novartis | CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) | In preparation |
| HR+ & HER2- | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | Astra Zeneca | CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI CISSS DE CHAUDIÈRE-APPALACHES | In recruitment |
| HR+ & HER2 low | DYNASTY-Breast-02 A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) | DualityBio | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL/ ST. MARY'S HOSPITAL | In recruitment |
| HR+ or HR- & HER2+ or HER2- | EXActDNA-003 (Exact 2023-05) NSABP B-64Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease | Exact Sciences Corporation & NSABP | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CHU DE QUEBEC - UNIVERSITÉ LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT | In preparation |
| HR+ & HER2- | MK-2870-010 An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer | Merck | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT | In preparation |
| HR- & HER2- | MK-2870-012 A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery | Merck | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE | In preparation |
| HR+ & HER2- | OPERA-01 A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01) | Olema Pharmaceuticals | CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) | In recruitment |
| HR- & HER2- | TROPION-BREAST-05 A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Astra Zeneca | CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE | In recruitment |
| HR+ & HER2- | C439022 An interventional, open-label, randomized, multicenter phase 3 study of pf-07220060 plus fulvestrant compared to investigator’s choice of therapy in participants over 18 years of age with hormone receptor-positive, her2-negative advanced/metastatic breast cancer whose disease progressed after prior cdk 4/6 inhibitor based therapy. | Pfizer | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR+ & HER2- | C4391025 An interventional, open-label, randomized, multicenter, phase 2 study of pf-07220060 plus letrozole compared to letrozole alone in postmenopausal women 18 years or older with hormone receptor-positive, her2-negative breast cancer in the neoadjuvant setting | Pfizer | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) | In preparation |
| Cancer Subtype | Study Name | Sponsor | Participating Hospitals | Status |
|---|---|---|---|---|
| HR+/HER2- | SERENA-4 A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL | In recruitment |
| HR+/HER2- | CAPItello-292 A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HER2+ | HER2CLIMB-05 A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer | Seagen | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU SAGUENAY-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR- & HER2- (triple negative) | TROPION-Breast-03 A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response at the Time of Surgery Following Neoadjuvant Therapy | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) | In recruitment |
| HR+ & HER2- | CELC-G-301 A phase 3, open-label, randomized, two-part study comparing gedatolisib in combination with palbociclib and fulvestrant to standard-of-care therapies in patients with hr-positive, her2-negative advanced breast cancer previously treated with a cdk4/6 inhibitor in combination with non-steroidal aromatase inhibitor therapy (viktoria-1) | Celcuity | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR+ & HER2- | CAMBRIA-1 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer | Astra Zeneca | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In preparation |
| HR- & HER2- (triple négatif) | TROPION-Breast-04 A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer | Astra Zeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE - CHUS CISSS DE CHAUDIÈRE-APPALACHES | In recruitment |
| HR+ & HER2- | INAVO-121 A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy | Hoffmann-LaRoche | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU NORD-DE-L’ÎLE-DE-MONTRÉAL / HÔPITAL DU SACRÉ-CŒUR-DE-MONTRÉAL | In recruitment |
| HR+ or HR- & HER2+ | INAVO-122 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Hoffmann-LaRoche | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU NORD-DE-L’ÎLE-DE-MONTRÉAL / HÔPITAL DU SACRÉ-CŒUR-DE-MONTRÉAL | In recruitment |
| HR+ & HER2- | pionERA Breast Cancer A Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. | Hoffmann-LaRoche | CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR+ & HER2- | Adjuvant WIDER A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer | Novartis | CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) | In preparation |
| HR+ & HER2- | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | Astra Zeneca | CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI CISSS DE CHAUDIÈRE-APPALACHES | In recruitment |
| HR+ & HER2 low | DYNASTY-Breast-02 A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) | DualityBio | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL/ ST. MARY'S HOSPITAL | In recruitment |
| HR+ or HR- & HER2+ or HER2- | EXActDNA-003 (Exact 2023-05) NSABP B-64Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease | Exact Sciences Corporation & NSABP | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CHU DE QUEBEC - UNIVERSITÉ LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT | In preparation |
| HR+ & HER2- | MK-2870-010 An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer | Merck | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT | In preparation |
| HR- & HER2- | MK-2870-012 A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery | Merck | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE | In preparation |
| HR+ & HER2- | OPERA-01 A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01) | Olema Pharmaceuticals | CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) | In recruitment |
| HR- & HER2- | TROPION-BREAST-05 A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Astra Zeneca | CHU DE QUEBEC - UNIVERSITÉ LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM) CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE | In recruitment |
| HR+ & HER2- | C439022 An interventional, open-label, randomized, multicenter phase 3 study of pf-07220060 plus fulvestrant compared to investigator’s choice of therapy in participants over 18 years of age with hormone receptor-positive, her2-negative advanced/metastatic breast cancer whose disease progressed after prior cdk 4/6 inhibitor based therapy. | Pfizer | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR+ & HER2- | C4391025 An interventional, open-label, randomized, multicenter, phase 2 study of pf-07220060 plus letrozole compared to letrozole alone in postmenopausal women 18 years or older with hormone receptor-positive, her2-negative breast cancer in the neoadjuvant setting | Pfizer | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) | In preparation |